240 related articles for article (PubMed ID: 15226322)
1. Combined-modality therapy with gemcitabine and radiotherapy as a bladder preservation strategy: results of a phase I trial.
Kent E; Sandler H; Montie J; Lee C; Herman J; Esper P; Fardig J; Smith DC
J Clin Oncol; 2004 Jul; 22(13):2540-5. PubMed ID: 15226322
[TBL] [Abstract][Full Text] [Related]
2. Combined chemoradiotherapy with gemcitabine in patients with locally advanced inoperable transitional cell carcinoma of the urinary bladder and/or in patients ineligible for surgery: a phase I trial.
De Santis M; Bachner M; Cerveny M; Kametriser G; Steininger T; Königsberg R; Schratter-Sehn A; Sedlmayer F; Dittrich C
Ann Oncol; 2014 Sep; 25(9):1789-1794. PubMed ID: 24936582
[TBL] [Abstract][Full Text] [Related]
3. Phase I study of conformal radiotherapy with concurrent gemcitabine in locally advanced bladder cancer.
Sangar VK; McBain CA; Lyons J; Ramani VA; Logue JP; Wylie JP; Clarke NW; Cowan RA
Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):420-5. PubMed ID: 15667962
[TBL] [Abstract][Full Text] [Related]
4. Prospective quality-of-life assessment in patients receiving concurrent gemcitabine and radiotherapy as a bladder preservation strategy.
Herman JM; Smith DC; Montie J; Hayman JA; Sullivan MA; Kent E; Griffith KA; Esper P; Sandler HM
Urology; 2004 Jul; 64(1):69-73. PubMed ID: 15245938
[TBL] [Abstract][Full Text] [Related]
5. Combined-modality therapy with gemcitabine and radiation therapy as a bladder preservation strategy: long-term results of a phase I trial.
Oh KS; Soto DE; Smith DC; Montie JE; Lee CT; Sandler HM
Int J Radiat Oncol Biol Phys; 2009 Jun; 74(2):511-7. PubMed ID: 18977098
[TBL] [Abstract][Full Text] [Related]
6. Gemcitabine, cisplatin, and hyperfractionated accelerated radiotherapy for locally advanced non-small cell lung cancer.
Zwitter M; Kovac V; Smrdel U; Strojan P
J Thorac Oncol; 2006 Sep; 1(7):662-6. PubMed ID: 17409933
[TBL] [Abstract][Full Text] [Related]
7. Combined chemoradiation therapy with twice-weekly gemcitabine and cisplatin for organ preservation in muscle-invasive bladder cancer: long-term results of a phase 1 trial.
Azria D; Riou O; Rebillard X; Thezenas S; Thuret R; Fenoglietto P; Pouessel D; Culine S
Int J Radiat Oncol Biol Phys; 2014 Mar; 88(4):853-9. PubMed ID: 24368064
[TBL] [Abstract][Full Text] [Related]
8. Phase I study of twice-weekly gemcitabine and concomitant external-beam radiotherapy in patients with adenocarcinoma of the pancreas.
Pipas JM; Mitchell SE; Barth RJ; Vera-Gimon R; Rathmann J; Meyer LP; Wagman RS; Lewis LD; McDonnell C; Colacchio TA; Perez RP
Int J Radiat Oncol Biol Phys; 2001 Aug; 50(5):1317-22. PubMed ID: 11483344
[TBL] [Abstract][Full Text] [Related]
9. Gemcitabine based trimodality treatment in patients with muscle invasive bladder cancer: May neutrophil lymphocyte and platelet lymphocyte ratios predict outcomes?
Hurmuz P; Ozyigit G; Kilickap S; Esen CSB; Akdogan B; Ozen H; Akyol F
Urol Oncol; 2021 Jun; 39(6):368.e19-368.e29. PubMed ID: 33189528
[TBL] [Abstract][Full Text] [Related]
10. A phase I trial of weekly gemcitabine and concurrent radiotherapy in patients with locally advanced pancreatic cancer.
Ikeda M; Okada S; Tokuuye K; Ueno H; Okusaka T
Br J Cancer; 2002 May; 86(10):1551-4. PubMed ID: 12085203
[TBL] [Abstract][Full Text] [Related]
11. Phase I study of gemcitabine and radiotherapy plus cisplatin after transurethral resection as conservative treatment for infiltrating bladder cancer.
Caffo O; Fellin G; Graffer U; Valduga F; Bolner A; Luciani L; Tomio L; Galligioni E
Int J Radiat Oncol Biol Phys; 2003 Dec; 57(5):1310-6. PubMed ID: 14630267
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of conformal hypofractionated radiotherapy with concurrent gemcitabine in muscle-invasive bladder cancer.
Choudhury A; Swindell R; Logue JP; Elliott PA; Livsey JE; Wise M; Symonds P; Wylie JP; Ramani V; Sangar V; Lyons J; Bottomley I; McCaul D; Clarke NW; Kiltie AE; Cowan RA
J Clin Oncol; 2011 Feb; 29(6):733-8. PubMed ID: 21205754
[TBL] [Abstract][Full Text] [Related]
13. A phase I radiation dose-escalation study to determine the maximal dose of radiotherapy in combination with weekly gemcitabine in patients with locally advanced pancreatic adenocarcinoma.
Budiharto T; Haustermans K; Van Cutsem E; Van Steenbergen W; Topal B; Aerts R; Ectors N; Bielen D; Vanbeckevoort D; Goethals L; Verslype C
Radiat Oncol; 2008 Sep; 3():30. PubMed ID: 18808686
[TBL] [Abstract][Full Text] [Related]
14. Estimating optimal dose of twice-weekly gemcitabine for concurrent chemoradiotherapy in unresectable pancreatic carcinoma: mature results of GEMRT-01 Phase I trial.
Girard N; Mornex F; Bossard N; Ychou M; Chauffert B; Wautot V
Int J Radiat Oncol Biol Phys; 2010 Aug; 77(5):1426-32. PubMed ID: 20056351
[TBL] [Abstract][Full Text] [Related]
15. Radiation therapy and concurrent fixed dose amifostine with escalating doses of twice-weekly gemcitabine in advanced pancreatic cancer.
Yavuz AA; Aydin F; Yavuz MN; Ilis E; Ozdemir F
Int J Radiat Oncol Biol Phys; 2001 Nov; 51(4):974-81. PubMed ID: 11704320
[TBL] [Abstract][Full Text] [Related]
16. A phase I study of gemcitabine plus palliative radiation therapy for advanced lung cancer.
Choi B; Robins HI; Schiller J; Mehta M
Cancer Chemother Pharmacol; 2008 Dec; 63(1):175-9. PubMed ID: 18305938
[TBL] [Abstract][Full Text] [Related]
17. Phase I-II trial of twice-weekly gemcitabine and concomitant irradiation in patients undergoing pancreaticoduodenectomy with extended lymphadenectomy for locally advanced pancreatic cancer.
Joensuu TK; Kiviluoto T; Kärkkäinen P; Vento P; Kivisaari L; Tenhunen M; Westberg R; Elomaa I
Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):444-52. PubMed ID: 15380578
[TBL] [Abstract][Full Text] [Related]
18. Trimodalities for bladder cancer in elderly: Transurethral resection, hypofractionated radiotherapy and gemcitabine.
Mohamed HAH; Salem MA; Elnaggar MS; Gabr A; Abdelrheem AM
Cancer Radiother; 2018 May; 22(3):236-240. PubMed ID: 29678595
[TBL] [Abstract][Full Text] [Related]
19. Gemcitabine concurrent with thoracic radiotherapy after induction chemotherapy with gemcitabine/vinorelbine in locally advanced non-small cell lung cancer: a phase I study.
Gagel B; Piroth M; Pinkawa M; Reinartz P; Zimny M; Fischedik K; Stanzel S; Breuer C; Skobel E; Asadpour B; Schmachtenberg A; Buell U; Eble MJ
Strahlenther Onkol; 2006 May; 182(5):263-9. PubMed ID: 16673059
[TBL] [Abstract][Full Text] [Related]
20. Phase I study of concomitant gemcitabine and IMRT for patients with unresectable adenocarcinoma of the pancreatic head.
Crane CH; Antolak JA; Rosen II; Forster KM; Evans DB; Janjan NA; Charnsangavej C; Pisters PW; Lenzi R; Papagikos MA; Wolff RA
Int J Gastrointest Cancer; 2001; 30(3):123-32. PubMed ID: 12540024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
